Stellar Biotechnologies, Inc. (NASDAQ:SBOT) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition. |
On May 9, 2017, Stellar Biotechnologies, Inc. issued a press
release announcing its financial results for its fiscal quarter
ended March 31, 2017 (the Earnings Release). The full text of the
Earnings Release is attached hereto as Exhibit 99.1. The
information furnished herein and therein shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act
of 1934 (the Exchange Act) or otherwise subject to the
liabilities of that Section, or incorporated by reference in any
filing under the Exchange Act or the Securities Act of 1933, as
amended, except as shall be expressly set forth by specific
reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 |
Press release issued by Stellar Biotechnologies, Inc. dated May 9, 2017. |
About Stellar Biotechnologies, Inc. (NASDAQ:SBOT)
Stellar Biotechnologies, Inc. is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases. The Company’s core business is developing and commercializing Keyhole Limpet Hemocyanin for use in immunotherapy and immunodiagnostic applications. The Company’s Stellar KLH product offerings include Stellar KLH protein for conjugation and as carrier molecule in immunotherapy development; Stellar KLH protein and enzyme-linked immunosorbent assay (ELISA) test kits for immune function testing, and Custom KLH formulations, adjuvants, conjugations and fill finishes for preclinical research and drug development applications. Stellar Biotechnologies, Inc. (NASDAQ:SBOT) Recent Trading Information
Stellar Biotechnologies, Inc. (NASDAQ:SBOT) closed its last trading session down -0.01 at 1.32 with 13,098 shares trading hands.